In a nutshell This study investigated the long-term outcomes of MCL (mantle cell lymphoma) patients who received RIST (reduced-intensity allogenic stem cell transplant) therapy. The authors concluded that RIST may be curative in MCL patients, even in those who relapsed after autoSCT (autologous stem cell transplant). Some background Mantle cell...
Read MoreIn a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...
Read More
In a nutshell This study is a review of the effectiveness of rituximab maintenance therapy for patients with follicular lymphoma. The authors concluded rituximab maintenance improves survival outcomes for patients with follicular lymphoma. Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is most commonly treated...
Read More
In a nutshell This study looked at the effectiveness of bortezomib plus cyclophosphamide and rituximab at treating patients with relapsed mantle cell lymphoma. The study concluded that this combination of medication is safe and effective at treating patients with relapsed or difficult to treat mantle cell lymphoma. Some background Mantle...
Read MoreIn a nutshell The authors looked at increasing the dose of rituximab for elderly male patients with diffuse large B-cell lymphoma. The authors concluded that the higher dose improved patient outcomes and was just as safe as the lower dose. Some background Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma. It is...
Read More
In a nutshell This study examined the effectiveness of rituximab maintenance treatment for patients with diffuse large B-cell lymphoma (DLBCL). The review concluded that rituximab maintenance treatment increases progression-free survival in patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is a common type of...
Read More
In a nutshell The authors looked at relapses that occur in the central nervous system of patients with non-Hodgkin lymphoma who were treated with EPOCH chemotherapy and rituximab. The authors concluded that there is no increased risk of CNS relapse when treated with EPOCH-R compared with previous treatments. Some background Many forms of...
Read More
In a nutshell This study looks at the outcomes for patients over 80 years old who have diffuse large B-cell lymphoma. The study concluded that patients over 80 had significantly better outcomes when treated with rituximab and anthracycline-based chemotherapy, such as the R-CHOP treatment. Some background Diffuse large B-cell lymphoma (DLBCL)...
Read More
In a nutshell The authors examined whether rituximab was associated with the development of a second cancer after treatment for diffuse large B-cell lymphoma. The authors concluded that the number of patients with certain cancers has increased after rituximab was introduced. Some background Diffuse large B-cell lymphoma (DLBCL) is a very...
Read More
